Ambrilia: Conference call and webcast for Octreotide Phase III preliminary results


    MONTREAL, Jan. 21 /CNW Telbec/ - Ambrilia Biopharma Inc. (TSX:AMB)
announced today that it will be hosting a conference call and webcast on
Tuesday, January 22 at 9:00 am ET, to discuss the Phase III preliminary
results for its proprietary prolonged-release formulation of Octreotide, C2L,
in acromegaly patients.
    Dr. Philippe Calais, President and Chief Executive Officer, and
Dr. Bonabes de Rougé, Executive Vice-President and Chief Scientific Officer,
will be joined by the principal investigator of the study, Professor Stafford
Lightman, Professor of Medicine, University of Bristol and Henry-Wellcome
Center for Integrative Neuroscience & Endocrinology (LINE), U.K.
    Interested parties may access the conference call by way of telephone or
webcast. The numbers to access the conference call are (416) 644-3415
(international) and 1(800) 733-7560 (toll free). The webcast will be available
on the Company's website at, Investors' section, Conference
calls and webcasts, and will be archived for 365 days.
    A replay of the call will be available on the Company's website at, Investors' section, Conference calls and webcasts, from
Tuesday, January 22, 11:00 am ET to Tuesday, January 29, 11:59 pm ET, and the
numbers to access the replay are (416) 640-1917 (international) and
1(877) 289-8525 (toll free) with access code 21260411.

    Ambrilia's forward-looking statements

    This press release contains forward-looking statements that reflect the
Company's current expectation regarding future events. These forward-looking
statements involve risks and uncertainties. Actual events could differ
materially from those projected herein and depend on a number of factors
including, but not limited to, changing market conditions, successful and
timely completion of clinical studies, uncertainties related to the regulatory
approval process, establishment of corporate alliances and other risks
detailed from time to time in the Company's filings. We refer you to the Risk
Factors section of the Company's Management's Discussion & Analysis of
Financial Condition and Results of Operations which contain a more exhaustive
analysis of the risks and uncertainties that are generally connected to the
business of the Company. Such statements are also based on various
assumptions, including the successful and timely completion of clinical
studies on Ambrilia's products demonstrating efficacy and safety for human
use, their successful commercialization within the forecasted timelines and
the attainment of the forecasted milestone payments and other revenues. While
Ambrilia anticipates that subsequent events and developments may cause
Ambrilia's views to change, Ambrilia specifically disclaims any obligation to
update these forward looking statements, unless obligated to do so by
applicable securities laws.


    Ambrilia Biopharma Inc. (TSX:AMB) is a biopharmaceutical company
dedicated to the discovery and development of novel treatments for viral
diseases and cancer. Ambrilia's product portfolio includes an HIV protease
inhibitor program (with lead compound PPL-100), an HIV integrase inhibitor
program, two new formulations of existing peptides (Octreotide and Goserelin),
other tumor targeted peptides such as PCK3145 and the Tumor and tumor
Vasculature Targeting (TVT) technology platform, as well as other anti-viral
programs. Exclusive worldwide rights to PPL-100 and its related compounds have
been granted to Merck & Co., Inc. in return for milestone payments and
royalties. Ambrilia's head office, research and development and manufacturing
facilities are located in Montreal with a regional office in France. For more
information, please visit the Company's web site:

For further information:

For further information: Julie M. Thibodeau, B.Sc., MBA, Director,
Communications, Ambrilia Biopharma Inc., (514) 751-2003, ext 235,,,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890